ClinicalTrials.gg
Active, not recruitingNCT06645665Updated Apr 2, 2026

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above

A Phase 1 interventional study of Bivalent RSV Vaccine (IN006) and Placebo in Respiratory Syncytial Virus Infections, sponsored by Shenzhen Shenxin Biotechnology Co., Ltd. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Shenzhen Shenxin Biotechnology Co., Ltd · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 30 studies in Respiratory Syncytial Virus Infections with a site in China — 8 open to participants now, 13 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · China.

Planned enrollment
12th of 25
240 · median 132
Started
2024
with 6 others
Phase 1
6 of 30
1 open now
Primary completion
2027-04
later than 8 of 12 live
Registered
20th of 30
by date

Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, this one is the 12th largest by planned enrollment of the 25 interventional ones that give a count, is one of 7 that started in 2024, is one of 6 in phase 1, reaches primary completion later than 8 of the 12 other live ones, and was the 20th registered.

Respiratory Syncytial Virus Infections

307 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 50 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

8 of the 30 studies in Respiratory Syncytial Virus Infections with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Respiratory Syncytial Virus Infections with a site in China, or all of them as a file.
02

Study summary

The study will evaluate the safety, tolerability, and immunogenicity of 3 dose levels of IN006 in healthy adults aged 18 Years and Above; of a revaccination of IN006 given approximately 12 months after the initial vaccination in older adults (aged ≥60 years).

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • mRNA Vaccine
  • IN006
  • Respiratory syncytial virus
  • Viral Diseases
  • Messenger RNA
  • Innorna
  • Shenxin
  • Vaccines
  • Respiratory tract infections
  • Safety
  • Reactogenicity
  • Immunogenicity
  • RSV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Healthy people aged 18-59 (Part 1) or ≥60 (Part 2), male or female.
  2. (BMI) in the range of 18 to 29 kg/m\^2.
  3. Laboratory tests, 12-lead , chest radiograph, vital signs and physical examination results are normal during the screening period, or abnormal results assessed by the investigator had no clinical significance; Subjects ≥60 years old with stable medical conditions, whose risk was considered controllable by the investigator, could also be enrolled.
  4. Women of childbearing age took effective within 2 weeks before joining the study, and the pregnancy test results before vaccination are negative. All male and female subjects of reproductive age voluntarily agree to use effective contraception from the signing of until 6 months after vaccination.

Key Exclusion Criteria:

  1. The results of vital signs show: for subjects with no history of hypertension or hypotension, systolic blood pressure ≥140mmHg or \< 90mmHg, and/or diastolic blood pressure ≥90mmHg or \< 50mmHg; for subject with a history of hypertension not appropriately controlled via pharmaceutical treatment, systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg in those aged 40-59, and systolic blood pressure ≥150mmHg or diastolic blood pressure ≥90mmHg in those aged 60 and above. Pulse rate > 100 beats/min or \< 50 beats/min; Ear temperature/oral temperature > 37.5°C (or axillary temperature > 37.0°C).
  2. Laboratory tests, 12-lead electrocardiogram, chest radiography (orthographic) and physical examination results: For subjects aged 18-59 years old, abnormal results judged to be by the investigator, or for subjects ≥60 years old, abnormal results judged to be > Grade 1 criteria by the investigator; For laboratory tests, a retest may be conducted at the discretion of investigators to determine subjects eligibility.
  3. Those with tattoos, scars and ecchymosis at the injection site.
  4. Known allergy to the experimental vaccine or its , or history of severe allergy to other vaccines, foods, drugs, etc.
  5. The subject has received any previous or marketed RSV vaccine, or has received investigational or marketed RSV prophylactic monoclonal antibody within the last 6 months.
  6. Received inactivated, subunit, or recombinant influenza vaccine within 14 days prior to enrollment, or received any , nucleic acid vaccine, or adenovirus vector vaccine within 28 days prior to enrollment; Or plan to receive other vaccines within 28 days of vaccination.
  7. Used antipyretic, analgesic or anti-allergic drugs within 3 days before enrollment.
  8. Have received blood or blood-related products (including immunoglobulins) within 3 months prior to enrollment, or had planned to use them during the study period.
  9. People with the following diseases:

    • A history of acute respiratory infection within 2 weeks of vaccination or a history of confirmed RSV-associated respiratory infection within 3 months prior to vaccination;
    • History of congenital or acquired immune deficiency or disease, or long-term use (continuous use > 14 days) of (dose ≥20mg/ day prednisone or equivalent dose) or other within the past 6 months;
    • people who are known to have been diagnosed with or currently have infectious diseases (including , , syphilis, and acquired immunodeficiency syndrome), or whose test positive for any of the hepatitis B surface antigens, hepatitis C antibodies, treponema pallidum antibodies, or antibodies;
    • A history or family history of neurological disease (convulsions, seizures, etc.); History or family history of mental illness;
    • Asplenia, or functional asplenia;
    • A history of myocarditis, pericarditis, or idiopathic cardiomyopathy, or any condition that increases the risk of myocarditis or pericarditis;
    • History of inflammatory demyelinating neuropathy such as Guillain-Barre syndrome;
    • Severe cardiovascular diseases, diabetes, blood and lymphatic system diseases, immune system diseases, liver and kidney diseases, respiratory diseases, metabolic and skeletal diseases, or malignant tumors (excluding stable chronic medical history, such as diabetes, hypertension, etc.);
    • to intramuscular injection and blood drawing;
    • A history of tuberculosis (TB) or a positive T-cell test for TB infection (T-SPOT).
  10. Had a history of major surgery within 3 months prior to vaccination or planned surgery during the trial.
  11. Abuser of Drug or alcohol in the year prior to screening, which the investigator believes that it may impact on subjects' safety assessment or compliance.
  12. Women of childbearing age who are breastfeeding, pregnant, have positive pregnancy test results or plan to become pregnant within 6 months after participating in the study.
  13. Those who have received a vaccine or drug involving lipid nanoparticles (LNP) within 1 year, are participating in other RSV-related clinical trials, and are in or plan to participate in other clinical trials during the study period.
  14. The investigator assesses that the subject has any disease or condition that would place the subject at an unacceptable risk; The subject is unable to meet protocol requirements; Conditions that interfere with the assessment of vaccine response.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Dose A in Younger Adults

    Single injection of Dose A of IN006 or matching-placebo on Day 0

    Biological: Bivalent RSV Vaccine (IN006) · Biological: Placebo

  • Experimental
    Cohort 2: Dose B in Younger Adults

    Single injection of Dose B of IN006 or matching-placebo on Day 0.

    Biological: Bivalent RSV Vaccine (IN006) · Biological: Placebo

  • Experimental
    Cohort 3: Dose C in Younger Adults

    Single injection of Dose C of IN006 or matching-placebo on Day 0.

    Biological: Bivalent RSV Vaccine (IN006) · Biological: Placebo

  • Experimental
    Cohort 4: Dose A in Older Adults

    One injection of either Dose A of IN006 or matching-placebo on Day 0. Participants who initially assigned to receive IN006 on Day 0 will be further randomized to receive a second injection of either IN006 or matching-placebo approximately 12 months later.

    Biological: Bivalent RSV Vaccine (IN006) · Biological: Placebo

  • Experimental
    Cohort 5: Dose B in Older Adults

    One injection of either Dose B of IN006 or matching-placebo on Day 0. Participants who initially assigned to receive IN006 on Day 0 will be further randomized to receive a second injection of either IN006 or matching-placebo approximately 12 months later.

    Biological: Bivalent RSV Vaccine (IN006) · Biological: Placebo

  • Experimental
    Cohort 6: Dose C in Older Adults

    One injection of either Dose C of IN006 or matching-placebo on Day 0. Participants who initially assigned to receive IN006 on Day 0 will be further randomized to receive a second injection of either IN006 or matching-placebo approximately 12 months later.

    Biological: Bivalent RSV Vaccine (IN006) · Biological: Placebo

Interventions

  • BiologicalBivalent RSV Vaccine (IN006)

    Formulation for injection

  • BiologicalPlacebo

    0.9% sodium chloride (normal saline) injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Solicited Local and Systemic Adverse Reactions Through 14 Days After Initial Vaccination

    Time frame: From initial vaccination up to14 days post initial vaccination

  2. Percentage of Participants With Unsolicited Adverse Events (AEs) Through 28 Days After Initial Vaccination

    Time frame: From initial vaccination up to 28 days post initial vaccination

  3. Percentage of Participants With AEs Through 30 Minutes After Initial Vaccination

    Time frame: From initial vaccination up to 30 minutes post initial vaccination

  4. Percentage of Participants With Any Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) During Study

    Time frame: Through study completion, about 2 years at most

  5. Percentage of Abnormal Results of Hematology On Day 3 After Initial Vaccination Compared with Baseline

    Time frame: From initial vaccination up to day 3 post initial vaccination

  6. Percentage of Abnormal Results of Clinical Chemistry On Day 3 After Initial Vaccination Compared with Baseline

    Time frame: From initial vaccination up to day 3 post initial vaccination

  7. Percentage of Abnormal Results of Coagulation On Day 3 After Initial Vaccination Compared with Baseline

    Time frame: From initial vaccination up to day 3 post initial vaccination

  8. Percentage of Participants With Any AEs Leading to Discontinuation of Vaccination or Withdrawal From The Study

    Time frame: Through study completion, about 2 years at most

Secondary outcomes

  1. Geometric mean concentration (GMC) for Pre-F Specific IgG Antibody Against RSV A and RSV B

    Time frame: Before vaccination, and 2 weeks and 1, 3, 6 and 12 months post-vaccination (Part 1, participants aged 18 to 59 years); before vaccination, and 2 weeks and 1, 3, 6 and 12 months post-initial vaccination (Part 2, participants aged ≥60 years)

  2. Geometric Mean Fold Rise (GMFR) for Pre-F Specific IgG Antibody Against RSV A and RSV B

    Time frame: Before vaccination, and 2 weeks and 1, 3, 6 and 12 months post-vaccination (Part 1, participants aged 18 to 59 years); before vaccination, and 2 weeks and 1, 3, 6 and 12 months post-initial vaccination (Part 2, participants aged ≥60 years)

  3. Seroconversion Rate (SCR) for Pre-F Specific IgG Antibody Against RSV A and RSV B

    Time frame: Before vaccination, and 2 weeks and 1, 3, 6 and 12 months post-vaccination (Part 1, participants aged 18 to 59 years); before vaccination, and 2 weeks and 1, 3, 6 and 12 months post-initial vaccination (Part 2, participants aged ≥60 years)

  4. Geometric mean titer (GMT) for Neutralizing Antibody Against RSV A and RSV B

    Time frame: Before vaccination, and 2 weeks and 1, 3, 6 and 12 months post-vaccination (Part 1, participants aged 18 to 59 years); before vaccination, and 2 weeks and 1, 3, 6 and 12 months post-initial vaccination (Part 2, participants aged ≥60 years)

  5. GMFR for Neutralizing Antibody Against RSV A and RSV B

    Time frame: Before vaccination, and 2 weeks and 1, 3, 6 and 12 months post-vaccination (Part 1, participants aged 18 to 59 years); before vaccination, and 2 weeks and 1, 3, 6 and 12 months post-initial vaccination (Part 2, participants aged ≥60 years)

  6. SCR for Neutralizing Antibody Against RSV A and RSV B

    Time frame: Before vaccination, and 2 weeks and 1, 3, 6 and 12 months post-vaccination (Part 1, participants aged 18 to 59 years); before vaccination, and 2 weeks and 1, 3, 6 and 12 months post-initial vaccination (Part 2, participants aged ≥60 years)

  7. Frequency of antigen Specific IFN-γ/IL-4 Secreting T cells (Via Enzyme-Linked Immunospot [ELISpot] Assay)

    Time frame: Before vaccination, and 2 weeks and 1, 3 and 6 months post-vaccination (Part 1, participants aged 18 to 59 years); before vaccination, and 2 weeks and 1, 3 and 6 months post-initial vaccination (Part 2, participants aged ≥60 years)

  8. Frequency of antigen Specific CD4 and CD8 T Cells Expressing Activation Markers (Via Intracellular Cytokine Staining [ICS] Assay)

    Time frame: Before vaccination, and 2 weeks post-vaccination (Part 1, participants aged 18 to 59 years); before vaccination, and 2 weeks and 1 month post-initial vaccination (Part 2, participants aged ≥60 years)

  9. Percentage of Participants (Part 2, Aged ≥60 Years) With Solicited Local and Systemic Adverse Reactions Through 14 Days After Revaccination

    Time frame: From second vaccination up to 14 days post revaccination

  10. Percentage of Participants (Part 2, Aged ≥60 Years) With Unsolicited AEs Through 28 Days After Revaccination

    Time frame: From second vaccination up to 28 days post revaccination

  11. Percentage of Participants With AEs Through 30 Minutes After Revaccination (Part 2, Aged ≥60 Years)

    Time frame: From second vaccination up to 30 Minutes post revaccination

  12. Percentage of Abnormal Results of Hematology On Day 3 After Revaccination Compared with Baseline of Revaccination (Part 2, Aged ≥60 Years)

    Time frame: From second vaccination up to Day 3 post revaccination

  13. Percentage of Abnormal Results of Clinical Chemistry On Day 3 After Revaccination Compared with Baseline of Revaccination (Part 2, Aged ≥60 Years)

    Time frame: From second vaccination up to Day 3 post revaccination

  14. Percentage of Abnormal Results of Coagulation On Day 3 After Revaccination Compared with Baseline of Revaccination (Part 2, Aged ≥60 Years)

    Time frame: From second vaccination up to Day 3 post revaccination

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Apr 2027, 29 months after the start.

Of 44 industry-sponsored phase 1 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's planned 29 months is above that.

Counting every sponsor, half of 57 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2024
First posted
Oct 17, 2024
StartActual
Nov 11, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06645665
Lead sponsor
Shenzhen Shenxin Biotechnology Co., Ltd
Responsible party
Sponsor
First posted
Oct 17, 2024
Start date
Nov 11, 2024
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Apr 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion